Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sami Mahrus

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Bioanalysis|August 25, 2018
A validated surrogate analyte LC-MS/MS assay for quantitation of endogenous kynurenine and tryptophan in human plasmaDennis Miller, Lei Tan, Drew Dorshorst, et al.
Journal of Virology|January 5, 2002
Altered substrate specificity of drug-resistant human immunodeficiency virus type 1 proteaseDeborah S Dauber, Rainer Ziermann, Neil Parkin, et al.
Journal of Hepatocellular Carcinoma|April 24, 2025
Atezolizumab Plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Real-World Experience From a US Community Oncology NetworkDavid Cosgrove, Ruoding Tan, Andrew J Osterland, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2022
Replication of Overall Survival, Progression-Free Survival, and Overall Response in Chemotherapy Arms of Non-Small Cell Lung Cancer Trials Using Real-World DataThanh G N Ton, Navdeep Pal, Huong Trinh, et al.
Molecular & Cellular Proteomics : MCP|December 25, 2012
The DegraBase: a database of proteolysis in healthy and apoptotic human cellsEmily D Crawford, Julia E Seaman, Nick Agard, et al.
The Lancet. Oncology|January 24, 2025
Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b-2, studyRichard S Finn, Baek-Yeol Ryoo, Chih-Hung Hsu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2016
Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid TumorsJeffrey R Infante, Antoine Hollebecque, Sophie Postel-Vinay, et al.
Journal for Immunotherapy of Cancer|June 21, 2018
Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumorsAsha Nayak-Kapoor, Zhonglin Hao, Ramses Sadek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2019
Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid TumorsKyung Hae Jung, Patricia LoRusso, Howard Burris, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Bioanalysis|August 25, 2018
A validated surrogate analyte LC-MS/MS assay for quantitation of endogenous kynurenine and tryptophan in human plasmaDennis Miller, Lei Tan, Drew Dorshorst, et al.
Journal of Virology|January 5, 2002
Altered substrate specificity of drug-resistant human immunodeficiency virus type 1 proteaseDeborah S Dauber, Rainer Ziermann, Neil Parkin, et al.
Journal of Hepatocellular Carcinoma|April 24, 2025
Atezolizumab Plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Real-World Experience From a US Community Oncology NetworkDavid Cosgrove, Ruoding Tan, Andrew J Osterland, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2022
Replication of Overall Survival, Progression-Free Survival, and Overall Response in Chemotherapy Arms of Non-Small Cell Lung Cancer Trials Using Real-World DataThanh G N Ton, Navdeep Pal, Huong Trinh, et al.
Molecular & Cellular Proteomics : MCP|December 25, 2012
The DegraBase: a database of proteolysis in healthy and apoptotic human cellsEmily D Crawford, Julia E Seaman, Nick Agard, et al.
The Lancet. Oncology|January 24, 2025
Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b-2, studyRichard S Finn, Baek-Yeol Ryoo, Chih-Hung Hsu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2016
Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid TumorsJeffrey R Infante, Antoine Hollebecque, Sophie Postel-Vinay, et al.
Journal for Immunotherapy of Cancer|June 21, 2018
Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumorsAsha Nayak-Kapoor, Zhonglin Hao, Ramses Sadek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2019
Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid TumorsKyung Hae Jung, Patricia LoRusso, Howard Burris, et al.
Pageof 2